Finland's Solu Raises €1 Million, Partners With Stanford And Plans A Pathogen Dna Library To Speed Up The Identification Of Antibiotic Resistance
PRIVATEJun 16, 2023
Amount Raised
€1 Million
Round Type
Seed
HelsinkiBiotechnologyEducation
Investors
Wave VenturesLifeline Ventures
Description
Finnish biotech start-up Solu has raised €1 million in funding to fuel the development and commercialisation of its product as it plans to builds an extensive pathogen DNA library
Who to call at Solu, and when
A new round usually means Solu is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Solu raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Solu, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Solu. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Solu
Location
Helsinki, Uusimaa, Finland
About
Antibiotic resistance is a leading health threat, and whole genome sequencing is the most accurate way to study pathogens. We make it easier to understand, detect and prevent the spread of antibiotic resistance.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Solu raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.